Literature DB >> 11710535

Factors modifying the migration of lymphocytes across the blood-brain barrier.

K A Brown1.   

Abstract

Characterising the factors that control the entry of leucocytes into tissue in response to inflammatory or microbial insult continues to generate considerable interest. Of all the tissues studied it is probably that of the CNS which is the most fascinating because of the specialised properties of its blood vessel walls, which constitute the blood-brain barrier (BBB). In health, very few leucocytes penetrate the BBB but in disorders such as MS the barrier becomes compromised with the result that there is an intense infiltration of the CNS by T lymphocytes whose subsequent activity appears to underlie the onset and progression of disease. The purpose of this article is to summarise and assess recent literature pertaining to how lymphocytes bind to cerebral endothelial cells, migrate across the blood vessel walls and enter the CNS parenchyma. Particular emphasis is devoted to the cellular and molecular aspects of these events and addressing the questions of whether certain subsets of circulating T lymphocytes are more favourably disposed than others to CNS infiltration and whether entry is dependent upon the initial expression of distinct groups of adhesion molecules and upon the generation of chemotactic factors. This article also focuses upon identifying the key stages of lymphocyte migration across the BBB and their susceptibility to antagonism by therapeutic agents. It is intended that the review will provide a useful source of information and offer additional insights into the mechanisms controlling lymphocyte passage across the BBB during pathological disturbance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11710535     DOI: 10.1016/s1567-5769(01)00129-1

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  16 in total

Review 1.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

2.  Recombinant erythropoietin down-regulates IL-6 and CXCR4 genes in TNF-alpha-treated primary cultures of human microvascular endothelial cells: implications for multiple sclerosis.

Authors:  Jagannadha R Avasarala; Sastry S Konduru
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

3.  Chronic inorganic mercury exposure induces sex-specific changes in central TNFα expression: importance in autism?

Authors:  J Thomas Curtis; Yue Chen; Daniel J Buck; Randall L Davis
Journal:  Neurosci Lett       Date:  2011-08-31       Impact factor: 3.046

4.  Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice.

Authors:  Xiaomeng Ma; Ying Jiang; Aimin Wu; Xiaohong Chen; Rongbiao Pi; Mei Liu; Yingying Liu
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

5.  Early blood-brain barrier permeability in cerebella of PLSJL mice immunized with myelin basic protein.

Authors:  Sergei Spitsin; Carla Portocarrero; Timothy W Phares; Rhonda B Kean; Christine M Brimer; Hilary Koprowski; D Craig Hooper
Journal:  J Neuroimmunol       Date:  2008-04-11       Impact factor: 3.478

6.  Membrane saturated fatty acids and disease progression in multiple sclerosis patients.

Authors:  G M Hon; M S Hassan; S J van Rensburg; S Abel; R T Erasmus; T Matsha
Journal:  Metab Brain Dis       Date:  2009-11-05       Impact factor: 3.584

7.  Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.

Authors:  S Marckmann; E Wiesemann; R Hilse; C Trebst; M Stangel; A Windhagen
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

8.  Caspase-1 has a critical role in blood-brain barrier injury and its inhibition contributes to multifaceted repair.

Authors:  Hila Israelov; Orly Ravid; Dana Atrakchi; Daniel Rand; Shirin Elhaik; Yael Bresler; Rachel Twitto-Greenberg; Liora Omesi; Sigal Liraz-Zaltsman; Fabien Gosselet; Michal Schnaider Beeri; Itzik Cooper
Journal:  J Neuroinflammation       Date:  2020-09-09       Impact factor: 8.322

Review 9.  The Emerging Application of Itaconate: Promising Molecular Targets and Therapeutic Opportunities.

Authors:  Jiaqi Lin; Jinxuan Ren; Dave Schwinn Gao; Yi Dai; Lina Yu
Journal:  Front Chem       Date:  2021-05-12       Impact factor: 5.221

10.  Short- and long-term effects of interleukin-2 treatment on the sensitivity of periadolescent female mice to interleukin-2 and dopamine uptake inhibitor.

Authors:  James S Rankin; Steven S Zalcman; Youhua Zhu; Allan Siegel
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.